Maze Therapeutics Prices $150M Stock Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MAZE?
Source: seekingalpha
- Offering Size: Maze Therapeutics has priced its underwritten offering of 5.54 million shares at $23.50 each, along with pre-funded warrants for up to 850,000 shares at $23.499 each, aiming for gross proceeds of $150 million, which significantly bolsters its financial position.
- Use of Proceeds: The company intends to utilize the net proceeds primarily to advance research and development of its product candidates, as well as for general corporate purposes, which will enhance its ongoing innovation and competitiveness in the biopharmaceutical sector.
- Operational Funding Assurance: Maze expects that the net proceeds from this offering, combined with its current cash, cash equivalents, and marketable securities, will fund operations into 2029, ensuring the smooth execution of its R&D and market expansion plans over the coming years.
- Underwriting Arrangement: Leerink Partners is acting as the sole underwriter for the offering, which is expected to close around April 23, 2026, subject to customary closing conditions, reflecting the company's proactive approach in capital markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAZE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAZE
Wall Street analysts forecast MAZE stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.840
Low
46.00
Averages
52.00
High
60.00
Current: 26.840
Low
46.00
Averages
52.00
High
60.00
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Maze Therapeutics Prices 5.54 Million Share Offering at $23.50 Each
- Offering Size: Maze Therapeutics announced the pricing of 5,540,000 shares at $23.50 each, expecting gross proceeds of $150 million, which reflects strong market confidence in its product development.
- Investor Participation: The offering attracted both new and existing investors, including Farallon Capital and T. Rowe Price, indicating market recognition of Maze's future potential and enhancing its financing capabilities in the biopharmaceutical sector.
- Use of Proceeds: Maze intends to use the proceeds primarily to advance the research and development of MZE829 and MZE782, targeting APOL1-mediated kidney disease and phenylketonuria, showcasing the company's strategic focus in therapeutic areas.
- Financial Outlook: Maze expects that the net proceeds from this offering will fund operations into 2029, reflecting a long-term plan in financial management and R&D investment, thereby boosting investor confidence in its sustainable growth.
See More
Maze Therapeutics Prices $150M Stock Offering
- Offering Size: Maze Therapeutics has priced its underwritten offering of 5.54 million shares at $23.50 each, along with pre-funded warrants for up to 850,000 shares at $23.499 each, aiming for gross proceeds of $150 million, which significantly bolsters its financial position.
- Use of Proceeds: The company intends to utilize the net proceeds primarily to advance research and development of its product candidates, as well as for general corporate purposes, which will enhance its ongoing innovation and competitiveness in the biopharmaceutical sector.
- Operational Funding Assurance: Maze expects that the net proceeds from this offering, combined with its current cash, cash equivalents, and marketable securities, will fund operations into 2029, ensuring the smooth execution of its R&D and market expansion plans over the coming years.
- Underwriting Arrangement: Leerink Partners is acting as the sole underwriter for the offering, which is expected to close around April 23, 2026, subject to customary closing conditions, reflecting the company's proactive approach in capital markets.
See More
Maze Therapeutics Raises $150 Million in Stock Offering
- Offering Size: Maze Therapeutics announced an underwritten offering of 5.54 million shares at $23.50 each and 850,000 pre-funded warrants, expected to raise approximately $150 million, indicating strong market confidence in its R&D projects.
- R&D Focus: The proceeds will primarily advance the development of MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, highlighting the company's strategic emphasis on critical therapeutic areas.
- Funding Utilization: Maze expects that the net proceeds, combined with existing cash and marketable securities, will fund operations into 2029, ensuring its long-term R&D capabilities and market competitiveness.
- Market Reaction: Following the financing announcement, Maze Therapeutics' stock fell 4.28% to $25.69 on Nasdaq but rebounded 1.01% to $25.95 in after-hours trading, reflecting cautious optimism among investors regarding the company's future prospects.
See More
Maze Therapeutics Executive Sells Shares Amid Declining Stock Price
- Executive Stock Sale: Harold Bernstein, R&D President of Maze Therapeutics, sold 15,000 shares of common stock on April 1, 2026, for approximately $442,000, marking a complete exit from his direct holdings and indicating a strategic withdrawal from direct investment in the company.
- Options Exercise Context: The transaction was executed through the exercise of options, and Bernstein retains 237,407 outstanding stock options, suggesting he still has the potential to acquire shares in the future despite having no direct holdings.
- Market Reaction Analysis: Maze Therapeutics' stock price surged 208.05% over the past year, but after reaching a 52-week high of $53.65, the stock experienced a decline as investors began to cash in, which may correlate with Bernstein's sale.
- Investment Risk Advisory: While Bernstein's sale is not necessarily a negative signal as it was conducted under a Rule 10b5-1 trading plan, the company has yet to generate revenue and reported a net loss of $131.1 million in 2025, prompting investors to carefully assess the future approval prospects of its kidney drug, MZE829.
See More
Chief Medical Officer Sells All Shares
- Share Sale Details: Chief Medical Officer Harold Bernstein sold 15,000 shares of the company on April 1, 2026, for approximately $442,000 at around $29.46 per share, marking a complete exit from his direct Common Stock holdings.
- Transaction Context: The sale was executed through the exercise of options and immediate disposition, with Bernstein utilizing a Rule 10b5-1 trading plan adopted in September 2025 to avoid insider trading accusations, although he retains over 237,000 stock options.
- Market Reaction and Price Fluctuation: Bernstein's sale occurred during a decline in Maze Therapeutics' stock price, which had reached a 52-week high of $53.65 in March due to positive clinical trial data, but investors began cashing in on high valuations, leading to a price drop.
- Company Financial Status: Maze Therapeutics ended 2025 with a net loss of $131.1 million and currently does not generate revenue, indicating high investment risk, as investors must have confidence in the potential federal approval of its lead kidney drug, MZE829.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Maze Therapeutics Prices 5.54 Million Share Offering at $23.50 Each
- Offering Size: Maze Therapeutics announced the pricing of 5,540,000 shares at $23.50 each, expecting gross proceeds of $150 million, which reflects strong market confidence in its product development.
- Investor Participation: The offering attracted both new and existing investors, including Farallon Capital and T. Rowe Price, indicating market recognition of Maze's future potential and enhancing its financing capabilities in the biopharmaceutical sector.
- Use of Proceeds: Maze intends to use the proceeds primarily to advance the research and development of MZE829 and MZE782, targeting APOL1-mediated kidney disease and phenylketonuria, showcasing the company's strategic focus in therapeutic areas.
- Financial Outlook: Maze expects that the net proceeds from this offering will fund operations into 2029, reflecting a long-term plan in financial management and R&D investment, thereby boosting investor confidence in its sustainable growth.
See More
Maze Therapeutics Prices $150M Stock Offering
- Offering Size: Maze Therapeutics has priced its underwritten offering of 5.54 million shares at $23.50 each, along with pre-funded warrants for up to 850,000 shares at $23.499 each, aiming for gross proceeds of $150 million, which significantly bolsters its financial position.
- Use of Proceeds: The company intends to utilize the net proceeds primarily to advance research and development of its product candidates, as well as for general corporate purposes, which will enhance its ongoing innovation and competitiveness in the biopharmaceutical sector.
- Operational Funding Assurance: Maze expects that the net proceeds from this offering, combined with its current cash, cash equivalents, and marketable securities, will fund operations into 2029, ensuring the smooth execution of its R&D and market expansion plans over the coming years.
- Underwriting Arrangement: Leerink Partners is acting as the sole underwriter for the offering, which is expected to close around April 23, 2026, subject to customary closing conditions, reflecting the company's proactive approach in capital markets.
See More
Maze Therapeutics Raises $150 Million in Stock Offering
- Offering Size: Maze Therapeutics announced an underwritten offering of 5.54 million shares at $23.50 each and 850,000 pre-funded warrants, expected to raise approximately $150 million, indicating strong market confidence in its R&D projects.
- R&D Focus: The proceeds will primarily advance the development of MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, highlighting the company's strategic emphasis on critical therapeutic areas.
- Funding Utilization: Maze expects that the net proceeds, combined with existing cash and marketable securities, will fund operations into 2029, ensuring its long-term R&D capabilities and market competitiveness.
- Market Reaction: Following the financing announcement, Maze Therapeutics' stock fell 4.28% to $25.69 on Nasdaq but rebounded 1.01% to $25.95 in after-hours trading, reflecting cautious optimism among investors regarding the company's future prospects.
See More
Maze Therapeutics Executive Sells Shares Amid Declining Stock Price
- Executive Stock Sale: Harold Bernstein, R&D President of Maze Therapeutics, sold 15,000 shares of common stock on April 1, 2026, for approximately $442,000, marking a complete exit from his direct holdings and indicating a strategic withdrawal from direct investment in the company.
- Options Exercise Context: The transaction was executed through the exercise of options, and Bernstein retains 237,407 outstanding stock options, suggesting he still has the potential to acquire shares in the future despite having no direct holdings.
- Market Reaction Analysis: Maze Therapeutics' stock price surged 208.05% over the past year, but after reaching a 52-week high of $53.65, the stock experienced a decline as investors began to cash in, which may correlate with Bernstein's sale.
- Investment Risk Advisory: While Bernstein's sale is not necessarily a negative signal as it was conducted under a Rule 10b5-1 trading plan, the company has yet to generate revenue and reported a net loss of $131.1 million in 2025, prompting investors to carefully assess the future approval prospects of its kidney drug, MZE829.
See More
Chief Medical Officer Sells All Shares
- Share Sale Details: Chief Medical Officer Harold Bernstein sold 15,000 shares of the company on April 1, 2026, for approximately $442,000 at around $29.46 per share, marking a complete exit from his direct Common Stock holdings.
- Transaction Context: The sale was executed through the exercise of options and immediate disposition, with Bernstein utilizing a Rule 10b5-1 trading plan adopted in September 2025 to avoid insider trading accusations, although he retains over 237,000 stock options.
- Market Reaction and Price Fluctuation: Bernstein's sale occurred during a decline in Maze Therapeutics' stock price, which had reached a 52-week high of $53.65 in March due to positive clinical trial data, but investors began cashing in on high valuations, leading to a price drop.
- Company Financial Status: Maze Therapeutics ended 2025 with a net loss of $131.1 million and currently does not generate revenue, indicating high investment risk, as investors must have confidence in the potential federal approval of its lead kidney drug, MZE829.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
